C M Wei, C H Kim, V M Miller, J C Burnett Jr
Title and authors | Publication | Year |
---|---|---|
Therapeutic Peptides to Treat Myocardial Ischemia-Reperfusion Injury
C Rico, K Konate, E Josse, J Nargeot, S Barrère-Lemaire, P Boisguérin |
Frontiers in Cardiovascular Medicine | 2022 |
Toward a New Paradigm for Targeted Natriuretic Peptide Enhancement in Heart Failure
O Gidlöf |
Frontiers in physiology | 2021 |
The Effects of Vasonatrin Peptide on Fat Graft Viability: An Experimental Study
F Irmak, M Sizmaz, SS Sirvan, S Karsidag, A Ozagari |
Facial Plastic Surgery | 2021 |
Atrial Natriuretic Peptide: Structure, Function, and Physiological Effects: A Narrative Review.
Rao S, Pena C, Shurmur S, Nugent K |
Current cardiology reviews | 2021 |
Vasonatrin peptide, a synthetic natriuretic peptide, attenuates myocardial injury and oxidative stress in isoprenaline-induced cardiomyocyte hypertrophy
P Chang, X Zhang, W Chen, J Zhang, J Wang, X Wang, J Yu, X Zhu |
Peptides | 2021 |
Natriuretic Peptides as the Basis of Peptide Drug Discovery for Cardiovascular Diseases
Y Lerner, W Hanout, SF Ben-Uliel, S Gani, MP Leshem, N Qvit |
Current topics in medicinal chemistry | 2020 |
C-type natriuretic peptide attenuates renal osteodystrophy through inhibition of FGF-23/MAPK signaling
DD Zhang, YF Wu, WX Chen, Y Xu, SY Liu, HH Luo, GM Jiang, Y Wu, P Hu |
Experimental & molecular medicine | 2019 |
Heart Failure: From Research to Clinical Practice
S Islam |
2018 | |
A New Chimeric Natriuretic Peptide, CNAAC, for the Treatment of Left Ventricular Dysfunction after Myocardial Infarction
SM Zhang, HL Zhao, XM Gu, J Li, N Feng, YM Wang, R Fan, WS Chen, JM Pei |
Scientific Reports | 2017 |
Innovative Therapeutics
LM Meems, JC Burnett |
JACC: Basic to Translational Science | 2016 |
Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly Inhibit Circulating Neprilysin Activity in Heart Failure
N Vodovar, MF Séronde, S Laribi, E Gayat, J Lassus, JL Januzzi, R Boukef, S Nouira, P Manivet, JL Samuel, D Logeart, A Cohen-Solal, AM Richards, JM Launay, A Mebazaa |
JACC: Heart Failure | 2015 |
Cardiovascular and renal effect of CNAAC: An innovatively designed natriuretic peptide
S Zhang, X Geng, L Zhao, J Li, F Tian, N Feng, J Liu, L Cheng, J Pei |
European Journal of Pharmacology | 2015 |
Vasonatrin peptide attenuates myocardial ischemia-reperfusion injury in diabetic rats and underlying mechanisms
Z Shi, F Fu, L Yu, W Xing, F Su, X Liang, R Tie, L Ji, M Zhu, J Yu, H Zhang |
American journal of physiology. Heart and circulatory physiology | 2015 |
The Effects of Vasonatrin Peptide on Random Pattern Skin Flap Survival:
SP Wang, ZY Lan, W Xia, X Zhao, GJ Ma, B Liu, BH Pan, SZ Guo |
Annals of Plastic Surgery | 2014 |
Natriuretic peptides in animal models of cardiovascular disease:
DS Burley, JS Bice, GF Baxter |
Cardiovascular Endocrinology | 2014 |
Vasonatrin peptide stimulates both of the natriuretic peptide receptors, NPRA and NPRB
YS Jiang, JY Lei, Y Chen, J Jin |
Biochemical and Biophysical Research Communications | 2014 |
Investigation of Cenderitide Controlled Release Platforms for Potential Local Treatment of Cardiovascular Pathology
XW Ng, Y Huang, KL Liu, FY Boey, SS Venkatraman |
Journal of Pharmaceutical Sciences | 2014 |
Vasonatrin peptide, a novel protector of dopaminergic neurons against the injuries induced by n-methyl-4-phenylpyridiniums
HK Zhao, BY Chen, R Chang, JB Wang, F Ni, L Yang, XC Dong, SH Sun, G Zhao, W Fang, QR Ma, XL Wang, J Yu |
Peptides | 2013 |
AC-NP: A Novel Chimeric Peptide with Natriuretic and Vasorelaxing Actions
BY Chen, JK Chen, MZ Zhu, DL Zhang, JS Sun, JM Pei, HS Feng, XX Zhu, J Jin, J Yu, C Zoccali |
PloS one | 2011 |
Vasonatrin peptide, a new regulator of adiponectin and interleukin-6 production in adipocytes
B-Y Chen, R Tie, P Qu, M-Z Zhu, X-X Zhu, J Jin, J Yu |
Journal of Endocrinological Investigation | 2011 |
Novel Natriuretic Peptides: New Compounds and New Approaches
MW Vogel, HH Chen |
Current Heart Failure Reports | 2010 |
C-type natriuretic peptide: Structural studies, fragment synthesis, and preliminary biological evaluation in human osteosarcoma cell lines
N Shaikh, L Russo, E Papaleo, P Giannoni, LD Gioia, F Nicotra, R Quarto, L Cipolla |
Biopolymers | 2010 |
Protective effects of vasonatrin peptide against hypobaric hypoxia-induced pulmonary hypertension in rats
J Yu, HS Feng, BY Chen, P Qu, LB Liu, JK Chen, R Tie, XJ Huang, YF Zhao, XX Zhu, MZ Zhu |
Clinical and Experimental Pharmacology and Physiology | 2010 |
Protecting effects of vasonatrin peptide against carbon tetrachloride-induced liver fibrosis
BY Chen, P Qu, R Tie, MZ Zhu, XX Zhu, J Yu |
Regulatory Peptides | 2010 |
Natriuretic peptide drug leads from snake venom
S Vink, AH Jin, KJ Poth, GA Head, PF Alewood |
Toxicon | 2010 |
Vitamins & Hormones
KJ Hare, FK Knop |
Vitamins & Hormones | 2010 |
Designer natriuretic peptides
CY Lee, H Lieu, JC Burnett |
Journal of investigative medicine : the official publication of the American Federation for Clinical Research | 2009 |
ANP, BNP and CNP: Physiology and Pharmacology of the Cardiorenal Axis
CY Lee, JC Burnett |
Textbook of Nephro-Endocrinology | 2009 |
Structural Substrate Conditions Required for Neutral Endopeptidase-Mediated Natriuretic Peptide Degradation
K Pankow, A Schwiebs, M Becker, WE Siems, G Krause, T Walther |
Journal of Molecular Biology | 2009 |
Designer natriuretic peptides.
Lee CY, Lieu H, Burnett JC Jr |
Journal of investigative medicine : the official publication of the American Federation for Clinical Research | 2009 |
Insights into natriuretic peptides in heart failure: An update
J Korinek, G Boerrigter, SF Mohammed, JC Burnett |
Current Heart Failure Reports | 2008 |
Biology of the Natriuretic Peptides
A Martinez-Rumayor, AM Richards, JC Burnett, JL Januzzi |
The American Journal of Cardiology | 2008 |
Novel Bifunctional Natriuretic Peptides as Potential Therapeutics
DM Dickey, JC Burnett, LR Potter |
The Journal of biological chemistry | 2008 |
Natriuretic peptides and therapeutic applications
CY Lee, JC Burnett |
Heart Failure Reviews | 2007 |
Natriuretic peptides as therapeutic targets
S Mukaddam-Daher |
Expert Opinion on Therapeutic Targets | 2006 |
Inhibition of hypoxia-induced proliferation and collagen synthesis by vasonatrin peptide in cultured rat pulmonary artery smooth muscle cells
SY Lu, DS Wang, MZ Zhu, QH Zhang, YZ Hu, JM Pei |
Life Sciences | 2005 |
Receptor subtypes for vasonatrin peptide in renal glomeruli and arteries
GE Woodard, X Li, JA Rosado |
Regulatory Peptides | 2005 |
Gene transfer of a novel vasoactive natriuretic peptide stimulates cGMP and lowers blood pressure in mice
S Pan, R Gulati, CS Mueske, TA Witt, A Lerman, JC Burnett, RD Simari |
American journal of physiology. Heart and circulatory physiology | 2004 |
Differential responses of newborn pulmonary arteries and veins to atrial and C-type natriuretic peptides
JF Tolsa, Y Gao, FC Sander, AC Souici, A Moessinger, JU Raj |
American journal of physiology. Heart and circulatory physiology | 2002 |
Mechanism of Relaxations to Dendroaspis Natriuretic Peptide in Canine Coronary Arteries
E Collins, MP Bracamonte, JC Burnett, VM Miller |
Journal of Cardiovascular Pharmacology | 2000 |
Practical implications of current natriuretic peptide research
GA Sagnella |
Journal of Renin-Angiotensin-Aldosterone System | 2000 |
C-Type Natriuretic Peptide
CS Barr, P Rhodes, AD Struthers |
Peptides | 1996 |
Neuroendocrine changes in chronic cardiac failure
D P Nicholls, G N Onuoha, G McDowell, J S Elborn, M S Riley, A M Nugent, I C Steele, C Shaw, K D Buchanan |
Basic Research in Cardiology | 1996 |
The natriuretic peptide family
G McDOWELL, C Shaw, KD Buchanan, DP Nicholls |
European Journal of Clinical Investigation | 1995 |
Atrial natriuretic peptide and C-type natriuretic peptide in spontaneously hypertensive rats and their vasorelaxing actions in vitro
CM Wei, CH Kim, AA Khraibi, VM Miller, JC Burnett |
Hypertension | 1994 |
Designer natriuretic peptides
DG Gardner |
Journal of Clinical Investigation | 1993 |